Xiralite in Psoriatic Arthritis for longitudinal measurement of clinical activity using standardized biologic treatment

Xiralite in Psoriatic Arthritis for longitudinal measurement of clinical activity using standardized biologic treatment - XPLORE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006000

Enrollment

Registered

2014-04-07

Start date

2013-12-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L40.5 L40.0

Interventions

Group 1: Use of fluorescence-optical imaging Xiralite in therapy control of PsA-patients using biological treatment compared to clinical examination and ultrasound over 12 months period

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: patients with active psoriatic arthritis, in Routine care planned Etanercept-therapy

Exclusion criteria

Exclusion criteria: Sensibility to contrast agents, esp. ICG, wounded hands, allergy to iodine, hyperthyreosis, adenoma of the thyroid, focal or diffuse autonomy of thyroid, significant co-morbidity or uncontrolled disease that influences patients safety

Design outcomes

Primary

Measure	Time frame
Comparison of positive values of fluorescence-optical imaging to physical examination and ultrasound at baseline, week 4, week 12, week 24, week 36 and week 54.	—

Secondary

Measure	Time frame
Comparison of fluorescence-optical imaging, physical examination and ultrasound	—

Countries

Germany

Contacts

Public ContactFrank Behrens

Fraunhofer IMEProjektgruppe TMPc/o Universitätsklinikum Frankurt/Main

frank.behrens@ime.fraunhofer.de069-6301-7302

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026